Abstract
Introduction Despite continued advances that have led to improved survival of patients with multiple myeloma (MM) over the years,1 MM remains largely incurable with overall survival in patients who have progressed after proteasome inhibitor (PI), immunomodulatory drug (IMID), and anti-CD38 monoclonal antibody (MoAb) therapy measured in months.2 Chimeric antigen receptor T cell (CAR-T) therapy has yielded early impressive results in the relapsed/refractory setting, with B cell maturation antigen (BCMA) as the most studied target. This review will summarize the evolution of this therapy, early results, and future directions that incrementally continue to move us closer toward that elusive cure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
